163 related articles for article (PubMed ID: 33086305)
1. Comprehensive Molecular Characterization of Adenocarcinoma of the Gastroesophageal Junction Between Esophageal and Gastric Adenocarcinomas.
Suh YS; Na D; Lee JS; Chae J; Kim E; Jang G; Lee J; Min J; Ock CY; Kong SH; George J; Zhang C; Lee HJ; Kim JI; Kim SJ; Kim WH; Lee C; Yang HK
Ann Surg; 2022 Apr; 275(4):706-717. PubMed ID: 33086305
[TBL] [Abstract][Full Text] [Related]
2. Patients with esophageal adenocarcinoma showed better prognosis than those with adenocarcinoma of the gastroesophageal junction.
Huang Q; Cheng Y; Lew E; Shi J; Wiener D; Weber HC
J Dig Dis; 2023 Feb; 24(2):98-112. PubMed ID: 36970757
[TBL] [Abstract][Full Text] [Related]
3. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction.
Bornschein J; Wernisch L; Secrier M; Miremadi A; Perner J; MacRae S; O'Donovan M; Newton R; Menon S; Bower L; Eldridge MD; Devonshire G; Cheah C; Turkington R; Hardwick RH; Selgrad M; Venerito M; Malfertheiner P; ; Fitzgerald RC
Int J Cancer; 2019 Dec; 145(12):3389-3401. PubMed ID: 31050820
[TBL] [Abstract][Full Text] [Related]
5. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
6. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
[TBL] [Abstract][Full Text] [Related]
7. ERBB2 suppression decreases cell growth via apoptosis in gastrointestinal adenocarcinomas.
Arrington AK; Dahlberg PS; Davydova J; Vickers SM; Yamamoto M
Surgery; 2009 Aug; 146(2):213-9. PubMed ID: 19628076
[TBL] [Abstract][Full Text] [Related]
8. Time trends in the incidence of esophageal adenocarcinoma, gastric adenocarcinoma, and superficial esophagogastric junction adenocarcinoma.
Matsuno K; Ishihara R; Ohmori M; Iwagami H; Shichijyo S; Maekawa A; Kanesaka T; Yamamoto S; Takeuchi Y; Higashino K; Uedo N; Matsunaga T; Morishima T; Miyashiro I
J Gastroenterol; 2019 Sep; 54(9):784-791. PubMed ID: 30927083
[TBL] [Abstract][Full Text] [Related]
9.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-645, up-regulated in human adencarcinoma of gastric esophageal junction, inhibits apoptosis by targeting tumor suppressor IFIT2.
Feng X; Wang Y; Ma Z; Yang R; Liang S; Zhang M; Song S; Li S; Liu G; Fan D; Gao S
BMC Cancer; 2014 Aug; 14():633. PubMed ID: 25174799
[TBL] [Abstract][Full Text] [Related]
11. Single disease entity for both chromosomal instable subtype gastric adenocarcinoma and esophageal adenocarcinoma.
Huang Q
J Dig Dis; 2017 Jun; 18(6):319-322. PubMed ID: 28509354
[TBL] [Abstract][Full Text] [Related]
12. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas.
van Dekken H; Geelen E; Dinjens WN; Wijnhoven BP; Tilanus HW; Tanke HJ; Rosenberg C
Cancer Res; 1999 Feb; 59(3):748-52. PubMed ID: 9973227
[TBL] [Abstract][Full Text] [Related]
13. Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma.
Hjortland GO; Meza-Zepeda LA; Beiske K; Ree AH; Tveito S; Hoifodt H; Bohler PJ; Hole KH; Myklebost O; Fodstad O; Smeland S; Hovig E
BMC Cancer; 2011 Oct; 11():455. PubMed ID: 22014070
[TBL] [Abstract][Full Text] [Related]
14. Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma.
Yoon HH; Lewis MA; Foster NR; Sukov WR; Khan M; Sattler CA; Wiktor AE; Wu TT; Jenkins RB; Sinicrope FA
Int J Cancer; 2016 Oct; 139(7):1626-31. PubMed ID: 27198655
[TBL] [Abstract][Full Text] [Related]
15. [Adenocarcinoma arising in gastroesophageal junction: a reappraisal].
Zhang XH
Zhonghua Bing Li Xue Za Zhi; 2007 Jun; 36(6):363-5. PubMed ID: 17822618
[No Abstract] [Full Text] [Related]
16. Primary adenocarcinomas of lower esophagus, esophagogastric junction and gastric cardia: in special reference to China.
Wang LD; Zheng S; Zheng ZY; Casson AG
World J Gastroenterol; 2003 Jun; 9(6):1156-64. PubMed ID: 12800215
[TBL] [Abstract][Full Text] [Related]
17. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.
Hong YS; Kim J; Pectasides E; Fox C; Hong SW; Ma Q; Wong GS; Peng S; Stachler MD; Thorner AR; Van Hummelen P; Bass AJ
PLoS One; 2014; 9(10):e109440. PubMed ID: 25350844
[TBL] [Abstract][Full Text] [Related]
18. Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.
De Silva N; Schulz L; Paterson A; Qain W; Secrier M; Godfrey E; Cheow H; O'Donovan M; Lao-Sirieix P; Jobanputra M; Hochhauser D; Fitzgerald R; Ford H
Br J Cancer; 2015 Nov; 113(9):1305-12. PubMed ID: 26484410
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
Wang K; Johnson A; Ali SM; Klempner SJ; Bekaii-Saab T; Vacirca JL; Khaira D; Yelensky R; Chmielecki J; Elvin JA; Lipson D; Miller VA; Stephens PJ; Ross JS
Oncologist; 2015 Oct; 20(10):1132-9. PubMed ID: 26336083
[TBL] [Abstract][Full Text] [Related]
20. Prediction of tissue origin of adenocarcinomas in the esophagogastric junction by DNA methylation.
Zhang CD; Takeshima H; Sekine S; Yamashita S; Liu YY; Hattori N; Abe H; Yamashita H; Fukuda M; Imamura Y; Ushiku T; Katai H; Makino H; Watanabe M; Seto Y; Ushijima T
Gastric Cancer; 2022 Mar; 25(2):336-345. PubMed ID: 34557982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
